STAAR Surgical Company (STAA)
- Previous Close
33.00 - Open
32.54 - Bid 32.09 x 100
- Ask 32.21 x 100
- Day's Range
31.78 - 32.76 - 52 Week Range
26.66 - 52.68 - Volume
571,269 - Avg. Volume
811,753 - Market Cap (intraday)
1.58B - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
97.33 - EPS (TTM)
0.33 - Earnings Date Oct 30, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
49.54
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
www.staar.com1,056
Full Time Employees
December 29
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: STAA
View MorePerformance Overview: STAA
Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: STAA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: STAA
View MoreValuation Measures
Market Cap
1.62B
Enterprise Value
1.42B
Trailing P/E
97.33
Forward P/E
625.00
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.77
Price/Book (mrq)
3.86
Enterprise Value/Revenue
4.15
Enterprise Value/EBITDA
43.66
Financial Highlights
Profitability and Income Statement
Profit Margin
4.99%
Return on Assets (ttm)
3.66%
Return on Equity (ttm)
4.36%
Revenue (ttm)
332.94M
Net Income Avi to Common (ttm)
16.61M
Diluted EPS (ttm)
0.33
Balance Sheet and Cash Flow
Total Cash (mrq)
235.2M
Total Debt/Equity (mrq)
8.87%
Levered Free Cash Flow (ttm)
22.24M